<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03455725</url>
  </required_header>
  <id_info>
    <org_study_id>04747 (CLIN)</org_study_id>
    <nct_id>NCT03455725</nct_id>
  </id_info>
  <brief_title>CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial</brief_title>
  <acronym>CardiAMP CMI</acronym>
  <official_title>Randomized Controlled Pivotal Trial of Autologous Bone Marrow Cells Using the CardiAMP Cell Therapy System in Patients With Refractory Angina Pectoris and Chronic Myocardial Ischemia (CardiAMP CMI Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioCardia, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioCardia, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multi-center, 2:1 randomized (Treatment : Sham Control), sham-controlled,&#xD;
      double-blinded trial to compare treatment using the CardiAMP cell therapy system to sham&#xD;
      treatment&#xD;
&#xD;
      Treatment Group:&#xD;
&#xD;
      Subjects treated with aBMC using the CardiAMP cell therapy system&#xD;
&#xD;
      Sham Control Group:&#xD;
&#xD;
      Subjects treated with a Sham Treatment (no introduction of the Helix transendocardial&#xD;
      delivery catheter, no administration of aBMC)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2021</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, multi-center, 2:1 randomized (Treatment vs Sham Control), blinded trial comparing 2 paralel groups of patients with CMI treated with CardiAMP cell therapy system vs sham treatment.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Quadruple-blinded, placebo-controlled study. Patients, investigators, the CRO, core labs and the sponsor will be blinded for individual treatment adjudication.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Total Exercise Time on the treadmill using the Modified Bruce Protocol</measure>
    <time_frame>Baseline and 6 months visit</time_frame>
    <description>A superiority analysis with regards to change from Baseline in Total Exercise Time at the 6 months follow-up visit (using a Modified Bruce Protocol).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: overall survival at 6 months follow-up</measure>
    <time_frame>at 6 months follow-up</time_frame>
    <description>A non-inferiority analysis of overall survival at 6-months will be made comparing the Treatment group to the Sham Control group using a non-inferiority margin of 10%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Total Major adverse cardiac events (MACE) at 6 months follow-up</measure>
    <time_frame>from randomisation to 6 months follow-up</time_frame>
    <description>A non-inferiority analysis with regard to Total Major Adverse Cardiac Events (MACE: defined as death, cardiac hospitalization, non-fatal myocardial infarction and stroke) at 12 month follow-up, as adjudicated by an independent clinical endpoint classification (CEC) committee with 10% margin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Change from baseline in Total Exercise Time at 6 months follow-up</measure>
    <time_frame>Baseline and at 6 months follow-up</time_frame>
    <description>Superiority analysis with regards to change from baseline in Total Exercise Time on Exercise Tolerance Test (ETT) at 6 Month Follow-up Visit. Baseline (BL) is the average of (at least) two total exercise times measured during the screening period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Change of angina frequency (per week) at 12 months follow-up</measure>
    <time_frame>Baseline and at 12 months follow-up</time_frame>
    <description>Superiority analysis with regards to change in angina frequency (episodes per week) at 12 month follow-up Visit versus baseline angina frequency (per week).&#xD;
Participants self-reported angina episodes utilizing an electronic diary for 4 weeks at baseline (screening period) and in the 4 weeks before the 12-month follow-up visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Change of Angina Frequency (per week) at 6 months follow-up</measure>
    <time_frame>Baseline and at 6 months follow-up</time_frame>
    <description>Superiority analysis with regards to change in angina frequency at 6 month follow-up visit versus baseline (expressed as angina frequency per week).&#xD;
Participants self-reported angina episodes utilizing an electronic diary for 4 weeks at baseline and in the 4 weeks before the 6-month follow-up visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Total Major adverse cardiac events (MACE) at 12 months follow-up</measure>
    <time_frame>From randomisation to 12 month follow-up</time_frame>
    <description>Superiority analysis with regards to incidence of MACE from Randomization until the end of the 24 month follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Percentage of patients with at least 1 Serious Adverse Event (SAE)</measure>
    <time_frame>From randomization to 12 Months follow-up</time_frame>
    <description>Superiority analysis with regards to percentage of participants with at least one SAE. From randomization until the end of the 12 month follow-up period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">343</enrollment>
  <condition>Refractory Angina</condition>
  <condition>Chronic Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>CardiAMP cell therapy system</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Roll-in phase:&#xD;
Up to 10 subjects with refractory chronic myocardial ischemia CCS class III-IV will be treated in an unblinded, uncontrolled roll-in phase.&#xD;
In the subsequent randomized phase:&#xD;
Up to 333 subjects with refractory chronic myocardial ischemia CCS class III-IV will be randomized. Up to 222 Subjects will be randomized to treatment with the CardiAMP cell therapy system.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham procedure control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Randomized phase:&#xD;
Up to 333 subjects with refractory chronic myocardial ischemia CCS class III-IV will be randomized. Up to 111 subjects will be treated with a Sham Treatment (no introduction of trans endocardial delivery catheter and no administration of autologous cells)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CardiAMP Cell Therapy System</intervention_name>
    <description>The CardiAMP Cell Therapy system consists of the CardiAMP Potency Assay, the Helix/Morph intramyocardial delivery catheter system, and the CardiAMP Cell Separator. The system allows the investigator to identify patients with a high chance to respond to im autologous stem cell therapy (using the CardiAMP Cell Potency Assay), to isolate the stem cells from a bone marrow harvest at the point of care (using the CardiAMP CS system), and to percutaneously inject the autologous cells into the myocardium using the Helix/Morph delivery catheters.</description>
    <arm_group_label>CardiAMP cell therapy system</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham Treatment</intervention_name>
    <description>Patients will receive sham bone marrow procedure and a ventriculogram. A scripted sham percutaneous procedure will be performed</description>
    <arm_group_label>Sham procedure control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female 21 to 80 years of age&#xD;
&#xD;
          2. Canadian Cardiovascular Society (CCS) class III or IV chronic refractory angina.&#xD;
&#xD;
          3. Lack of control of angina symptoms despite maximum tolerated doses of anti-angina&#xD;
             drugs.&#xD;
&#xD;
          4. Evidence of inducible myocardial ischemia on baseline stress testing&#xD;
&#xD;
          5. Obstructive coronary disease unsuitable for conventional revascularization&#xD;
&#xD;
          6. Experience angina episodes at a minimum of 7 angina episodes per week (during a 4-week&#xD;
             screening period).&#xD;
&#xD;
          7. Able to complete an exercise tolerance test on the treadmill&#xD;
&#xD;
          8. Left ventricular ejection fraction of greater than or equal to 40% as measured by&#xD;
             echocardiography.&#xD;
&#xD;
          9. Qualification of a pre-procedure screening of bone-marrow aspiration&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Other cardiac or vascular system or other health-related criteria which may be seen in a&#xD;
        patient's history and physical examination.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Peter Altman, PhD</last_name>
    <phone>(650) 226 0135</phone>
    <email>info@biocardia.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Wisconsin Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cassondra Vander Ark, RN</last_name>
      <phone>608-265-0612</phone>
      <email>cav@medicine.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Amish Raval, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://biocardia.com</url>
    <description>company website</description>
  </link>
  <link>
    <url>http://cardiamp.com</url>
    <description>patient information website regarding CardiAMP Heart Failure trial</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 28, 2018</study_first_submitted>
  <study_first_submitted_qc>February 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2018</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiovascular Stem Cell Therapy</keyword>
  <keyword>Bone Marrow Mononuclear Stem Cells</keyword>
  <keyword>Intramyocardial Injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

